Content area
Full text
LATEST COMPANY ANNOUNCEMENT
BeiGene, Ltd.
Nasdaq : BGNE · SEHK : 6160 · SSE : 688235
Q1 FY2025
20 May 2025
Associate: Anne Ching
BeiGene Announces First Quarter 2025 Financial Results and Business Updates
May 07, 2025 6:00 AM
- First quarter 2025 total revenues increased 49% to $1.1 billion with BRUKINSA® (zanubrutinib) global sales increasing 62% to $792 million on strong demand growth versus first quarter 2024
- Achieved GAAP profitability and significantly improved operating cash flow
- Advanced late-stage hematology and solid tumor pipelines with plan to host Investor R&D Day on June 26
- Secured shareholder approval to rename the Company to BeOne Medicines Ltd. and redomicile to Switzerland
SAN CARLOS, Calif.--(BUSINESS WIRE)-- BeiGene , Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines, Ltd., today announced financial results and corporate updates from the first quarter 2025.
“We delivered another exceptional quarter, achieving our first quarter of GAAP profitability with continued global revenue growth. In the U.S., BRUKINSA remains the leader in new chronic lymphocytic leukemia (CLL) patient starts across all lines of therapy, and for the first time has become the overall BTKi market share leader,” said John V. Oyler, Co-Founder, Chairman, and CEO of BeiGene. “We’ve made significant strides across our late-stage hematology and solid tumor pipelines, with multiple proof-of-concept readouts expected this year across our broad portfolio of antibody-drug conjugates, multispecific antibodies and targeted protein degraders. With accelerating financial momentum and a diversified global footprint spanning six continents, we are well positioned — as we transition to BeOne Medicines and redomicile to Switzerland — to become one of the world’s most impactful oncology innovators.”
First Quarter 2025 Financial Snapshot
(Amounts in thousands of U.S. dollars and unaudited)
* For an explanation of our use of non-GAAP financial measures refer to the “Note Regarding Use of Non-GAAP Financial Measures” section later in this press release and for a reconciliation of each non-GAAP financial measure to the most comparable GAAP measures, see the table at the end of this press release.
First Quarter 2025 Financial Results
Revenue for the first quarter of 2025 was $1.1 billion, compared to $752 million in the prior-year period driven primarily by growth in BRUKINSA product sales in the...